In a recent statement on June 18, 2026, in Boulder, Colorado, KROMATID, a distinguished provider of structural genomic integrity analysis for the cell and gene therapy sector, revealed the appointment of Matthew Hemstreet as the new Chief Executive Officer. He takes over from the Interim CEO Terry Opgenorth. The company, known for its innovative solutions in the industry, made the significant announcement amid growth and transition, marking a strategic change in leadership.